Peter Iversen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi request reprint Orchidectomy and oestrogen therapy revisited
    P Iversen
    Department of Urology, Rigshospitalet, University of Copenhagen, Denmark
    Eur Urol 34:7-11. 1998
  2. ncbi request reprint Quality of life issues relating to endocrine treatment options
    P Iversen
    Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    Eur Urol 36:20-6. 1999
  3. ncbi request reprint Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6
    Peter Iversen
    Department of Urology, University of Copenhagen, Rigshospitalet and Herlev Hospital, Copenhagen, Denmark
    J Urol 172:1871-6. 2004
  4. ncbi request reprint Bicalutamide monotherapy for early stage prostate cancer: an update
    Peter Iversen
    Department of Urology, Rigshospitalet, University of Copenhagen, Denmark
    J Urol 170:S48-52; discussion S52-4. 2003
  5. ncbi request reprint Antiandrogen monotherapy: indications and results
    Peter Iversen
    Department of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Urology 60:64-71. 2002
  6. ncbi request reprint A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6
    P Iversen
    Department of Urology D 2112, University of Copenhagen, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark
    Eur Urol 42:204-11. 2002
  7. ncbi request reprint Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years
    Peter Iversen
    Departments of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Scand J Urol Nephrol 40:441-52. 2006
  8. doi request reprint Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years
    Peter Iversen
    Department of Urology, Rigshospitalet, Copenhagen, Denmark
    BJU Int 105:1074-81. 2010
  9. doi request reprint The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer
    Peter Iversen
    University of Copenhagen, Department of Urology D 2112, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Expert Rev Anticancer Ther 8:361-9. 2008
  10. ncbi request reprint Patients undergoing radical prostatectomy have a better survival than the background population
    Martin Andreas Røder
    Copenhagen Prostate Cancer Center, Rigshospitalet, 2200 Copenhagen N, Denmark
    Dan Med J 60:A4612. 2013

Collaborators

Detail Information

Publications49

  1. ncbi request reprint Orchidectomy and oestrogen therapy revisited
    P Iversen
    Department of Urology, Rigshospitalet, University of Copenhagen, Denmark
    Eur Urol 34:7-11. 1998
    ..The route of administration is a crucial factor in the genesis of cardiovascular toxicity and parenterally administered oestrogens may not entail the same risk. Further research in this area is warranted...
  2. ncbi request reprint Quality of life issues relating to endocrine treatment options
    P Iversen
    Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    Eur Urol 36:20-6. 1999
    ..Endocrine treatments with minimal adverse effects on quality of life will be increasingly favoured for patients with non-metastatic disease who are being treated for longer periods of time...
  3. ncbi request reprint Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6
    Peter Iversen
    Department of Urology, University of Copenhagen, Rigshospitalet and Herlev Hospital, Copenhagen, Denmark
    J Urol 172:1871-6. 2004
    ..We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer...
  4. ncbi request reprint Bicalutamide monotherapy for early stage prostate cancer: an update
    Peter Iversen
    Department of Urology, Rigshospitalet, University of Copenhagen, Denmark
    J Urol 170:S48-52; discussion S52-4. 2003
    ..The current evidence is considered to support 150 mg of the nonsteroidal antiandrogen bicalutamide for early stage prostate cancer...
  5. ncbi request reprint Antiandrogen monotherapy: indications and results
    Peter Iversen
    Department of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Urology 60:64-71. 2002
    ..Emerging evidence also supports the use of bicalutamide 150 mg, both as immediate monotherapy and as adjuvant therapy in early stage (localized or locally advanced) prostate cancer...
  6. ncbi request reprint A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6
    P Iversen
    Department of Urology D 2112, University of Copenhagen, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark
    Eur Urol 42:204-11. 2002
    ..To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer...
  7. ncbi request reprint Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years
    Peter Iversen
    Departments of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Scand J Urol Nephrol 40:441-52. 2006
    ..Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme...
  8. doi request reprint Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years
    Peter Iversen
    Department of Urology, Rigshospitalet, Copenhagen, Denmark
    BJU Int 105:1074-81. 2010
    ..To evaluate the efficacy and tolerability of bicalutamide 150 mg once-daily as immediate hormonal therapy in patients with prostate cancer or as adjuvant to radical prostatectomy or radiotherapy...
  9. doi request reprint The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer
    Peter Iversen
    University of Copenhagen, Department of Urology D 2112, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Expert Rev Anticancer Ther 8:361-9. 2008
    ..Bicalutamide 150 mg represents an alternative to castration for patients with locally advanced disease who wish to avoid the side effects associated with castration...
  10. ncbi request reprint Patients undergoing radical prostatectomy have a better survival than the background population
    Martin Andreas Røder
    Copenhagen Prostate Cancer Center, Rigshospitalet, 2200 Copenhagen N, Denmark
    Dan Med J 60:A4612. 2013
    ..The objective of this study was to investigate standardised relative survival and mortality ratio for patients undergoing radical prostatectomy for localized prostate cancer at our institution...
  11. ncbi request reprint Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program
    Peter Iversen
    Department of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Urology 63:928-33. 2004
    ....
  12. doi request reprint Radical prostatectomy in clinically localized high-risk prostate cancer: outcome of 231 consecutive patients
    Martin Andreas Røder
    Department of Urology, Copenhagen Biocenter and Biotech Research and Innovation Centre BRIC, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    Scand J Urol 47:19-25. 2013
    ..This study examined the outcome for high-risk localized PCa patients treated with RP...
  13. doi request reprint Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies?
    Kasper Drimer Berg
    Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    APMIS 121:257-65. 2013
    ..Although candidates for AS may be identified using standard biopsies, a considerable fraction of patients will be understaged. There is a need for more precise diagnostic tools to assess intraprostatic tumour growth...
  14. doi request reprint First Danish single-institution experience with radical prostatectomy: impact of surgical margins on biochemical outcome
    Marie Louise Vrang
    Urology Research Unit, Department of Urology, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
    Scand J Urol Nephrol 46:172-9. 2012
    ..This study aimed to investigate the impact of positive surgical margins (PSMs), stratified by location and extension, on biochemical outcome after radical retropubic prostatectomy (RRP)...
  15. doi request reprint Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer
    Martin Andreas Røder
    Department of Urology and The Finsen Laboratory, Rigshospitalet, University of Copenhagen, Denmark
    BJU Int 109:520-4. 2012
    ..To investigate serum testosterone levels as a predictor for biochemical failure (BF) after radical retropubic prostatectomy (RRP)...
  16. ncbi request reprint The third analysis of the bicalutamide Early Prostate Cancer programme
    Peter Iversen
    Department of Urology, Rigshospitalet, Copenhagen, Denmark
    BJU Int 97:438-9. 2006
  17. doi request reprint Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer
    Charlotte E Almasi
    The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Prostate 71:899-907. 2011
    ..The purpose of this study was to investigate the prognostic value of different forms of the urokinase receptor, uPAR, in serum from prostate cancer (PC) patients...
  18. doi request reprint Risk of biochemical recurrence and positive surgical margins in patients with pT2 prostate cancer undergoing radical prostatectomy
    Martin Andreas Røder
    Copenhagen Prostate Cancer Center, University of Copenhagen, Copenhagen, Denmark Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
    J Surg Oncol 109:132-8. 2014
    ..To investigate risk factors associated with positive surgical margins (PSM) and biochemical recurrence (BR) in organ confined tumors (pT2) after radical prostatectomy (RP) for localized prostate cancer (PCa)...
  19. ncbi request reprint [Radical prostatectomy in patients with advanced prostate cancer]
    Martin Andreas Røder
    Urologisk Forskningsenhed, Urologisk Klinik, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark
    Ugeskr Laeger 174:3160-1. 2012
    ..We report three patients in whom radical prostatectomy was performed despite the presence of metastases...
  20. doi request reprint Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation
    Kasper Drimer Berg
    Department of Urology, Rigshospitalet, University of Copenhagen, Denmark
    APMIS 119:239-46. 2011
    ....
  21. ncbi request reprint Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma
    Klaus Brasso
    Department of Urology, H S Rigshospitalet, University of Copenhagen, Cophenhagen, Denmark
    Prostate 66:503-13. 2006
    ..To examine the prognostic value of markers of bone metabolism (serum PINP, BAP, and CTX-I) and serum YKL-40 in metastatic prostate carcinoma (PC)...
  22. ncbi request reprint Robot-assisted radical prostatectomy is a safe procedure
    Frederik Birkebæk Thomsen
    Copenhagen Prostate Cancer Centre, Rigshospitalet, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen N, Denmark
    Dan Med J 60:A4696. 2013
    ..We present our departmental experience with robot-assisted radical prostatectomy and describe complications and early results for the first 239 consecutive patients...
  23. ncbi request reprint Active surveillance can reduce overtreatment in patients with low-risk prostate cancer
    Frederik Birkebaek Thomsen
    Department of Urology and the Urology Research Unit, Section 7521, Rigshospitalet, 2100 Copenhagen, Denmark
    Dan Med J 60:A4575. 2013
    ..Active surveillance has been proposed as an observation strategy to reduce overtreatment and limit curatively intended therapy to those patients who need it. We reported the first Danish results from an active surveillance cohort...
  24. doi request reprint C-type natriuretic peptide in prostate cancer
    Soeren Junge Nielsen
    Department of Clinical Biochemistry, Ringhospitalet, University of Copenhagen, Denmark
    APMIS 117:60-7. 2009
    ..2) vs. 15.1 pmol/l (10.4-23.2), p=0.002] but not enough to justify the use of N-terminal proCNP as a cancer marker. Further research is needed to establish whether measurement of proCNP-derived peptides may offer clinical information...
  25. doi request reprint Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy
    Thine Hvid
    The Centre of Inflammation and Metabolism, Department of Infectious Diseases, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
    Endocr Relat Cancer 20:621-32. 2013
    ..05) not observed in the patients (P=0.64). In response to endurance training, ADT-treated prostate cancer patients exhibited improved insulin sensitivity and body composition to a similar degree as eugonadal men...
  26. pmc First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients
    M Andreas Røder
    Department of Urology, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Afsnit 2112, 2100 Copenhagen Ø, Denmark
    Prostate Cancer 2011:236357. 2011
    ..Early Danish results in a population not subjected to screening demonstrate BRFS rates comparable with earlier reports from the prescreening era...
  27. ncbi request reprint Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue
    Pernille Autzen Usher
    The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Int J Cancer 113:870-80. 2005
    ..No immunoreactivity and/or mRNA expression of uPA, uPAR or PAI-1 was observed in cancer cells or in other epithelial cells in any of the cases...
  28. ncbi request reprint Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
    Per Olov Hedlund
    Department of Urology, Karolinska Hospital, Stockholm, Sweden
    Scand J Urol Nephrol 36:405-13. 2002
    ..The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects...
  29. ncbi request reprint Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program
    William A See
    Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    J Urol 168:429-35. 2002
    ..We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locally advanced prostate cancer...
  30. ncbi request reprint [Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients]
    Martin Andreas Røder
    Rigshospitalet, Abdominalcenteret, Urologisk Afdeling D
    Ugeskr Laeger 170:2554-8. 2008
    ..The optimal management of prostate cancer patients with lymph node metastasis remains controversial. In this article, the outcome in a consecutive group of patients with newly diagnosed lymph node positive prostate cancer is presented...
  31. doi request reprint Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
    Per Olov Hedlund
    Department of Urology, Karolinska University Hospital Solna, Sweden
    Scand J Urol Nephrol 42:220-9. 2008
    ..The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular events...
  32. ncbi request reprint Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme
    Chris J Tyrrell
    Derriford Hospital, Plymouth, UK
    Radiother Oncol 76:4-10. 2005
    ....
  33. ncbi request reprint Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
    Chris J Tyrrell
    Derriford Hospital, Plymouth, UK
    BJU Int 98:563-72. 2006
    ....
  34. ncbi request reprint Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years
    Manfred P Wirth
    Department of Urology, Technical University of Dresden, Dresden, Germany
    J Urol 172:1865-70. 2004
    ..We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer...
  35. ncbi request reprint Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
    David G McLeod
    Walter Reed Army Medical Center, Washington, DC, USA
    BJU Int 97:247-54. 2006
    ..To evaluate, in the ongoing Early Prostate Cancer (EPC) trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer...
  36. ncbi request reprint [Prostatic cancer screening]
    Klaus Brasso
    Amtssygehuset i Gentofte, Urologisk afdeling H, H S Rigshospitalet, Urologisk Afdeling D
    Ugeskr Laeger 164:155-7. 2002
  37. ncbi request reprint [Metastatic prostatic cancer]
    Peter Iversen
    Ugeskr Laeger 165:2083. 2003
  38. ncbi request reprint Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 170:S3-5. 2003
  39. ncbi request reprint Chemotherapeutic prevention studies of prostate cancer
    Bob Djavan
    Department of Urology, Prostate Disease Center, Ludwig Boltzmand Institute for Prostatic disease, University of Vienna, Wahringer Gurtel 18 20, 1090, Austria
    J Urol 171:S10-3; discussion S13-4. 2004
    ..We review prostate cancer chemoprevention studies in Europe...
  40. ncbi request reprint [Prostatic cancer 2006--status and new challenges. The Danish Society of Urology]
    Klaus Brasso
    Urologisk Afdeling D, H S Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 168:1243. 2006
  41. ncbi request reprint Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 172:S3-5. 2004
  42. ncbi request reprint [Prostate cancer in Denmark 1943-2002]
    Klaus Brasso
    Rigshospitalet, Urologisk Afdeling D
    Ugeskr Laeger 169:129-32. 2007
    ..This study reviews the trends in PC incidence and mortality rates in Denmark during the 60-year-period from 1943 to 2002...
  43. ncbi request reprint Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival
    Julia S Johansen
    Department of Rheumatology, Herlev Hospital, Denmark
    Clin Cancer Res 13:3244-9. 2007
    ..In this study, we evaluated the value of these biomarkers in monitoring the patients during hormonal treatment...
  44. ncbi request reprint [Screening for prostate cancer--what does the evidence show?]
    Michael Borre
    Arhus Universitetshospital, Skejby
    Ugeskr Laeger 169:1887-8. 2007
    ..Until ongoing large, randomised screening trials mature and produce results that may prove otherwise, the Danish policy of not recommending PSA-based screening should be upheld...
  45. ncbi request reprint [Treatment of localised prostate cancer]
    Henrik Jakobsen
    Herlev Hospital, Urologisk afdeling H, Rigshospitalet, Urologisk Afdeling D
    Ugeskr Laeger 169:1902-4. 2007
    ..In older patients with good prognostic factors, active surveillance should be considered. The various therapeutic modalities are reviewed...
  46. ncbi request reprint [Organisation and early outcome after radical prostatectomy in Denmark 2004-2007]
    Michael Borre
    Universitetshospital, Skejby, Urinvejskirurgisk Afdeling, Rigshospitalet, Urologisk Afdeling
    Ugeskr Laeger 170:2545-9. 2008
    ..The organisation, volume and early morbidity after radical prostatectomy has not been researched in Denmark...
  47. ncbi request reprint [Prostatic Cancer Patient Association PROPA--and information about prostatic cancer]
    Peter Iversen
    Ugeskr Laeger 170:2897. 2008
  48. ncbi request reprint [Radical prostatectomy versus observation for localized prostatic cancer]
    Peter Iversen
    Urologisk Afdeling D, H S Rigshopitalet
    Ugeskr Laeger 165:139-40. 2003
  49. ncbi request reprint Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients
    Johan Stranne
    Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden
    Urology 65:847-51. 2005
    ..IH has been reported in 12% to 21% of men at a mean period of 6 to 10 months after RRP. However, whether IH truly represents a complication after RRP has been somewhat debatable owing to the lack of proper control groups...